Tristan Römer1, Norbert Wagner2, Till Braunschweig3, Robert Meyer4, Miriam Elbracht4, Udo Kontny2, Olga Moser2. 1. Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Pauwelstrasse 30, 52074, Aachen, Germany. troemer@ukaachen.de. 2. Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Pauwelstrasse 30, 52074, Aachen, Germany. 3. Institute of Pathology, RWTH Aachen University, Aachen, Germany. 4. Institute of Human Genetics, RWTH Aachen University, Aachen, Germany.
Abstract
BACKGROUND: Infantile myofibromatosis (IM) is the most common cause of multiple fibrous tumors in infancy. Multicentric disease can be associated with life-threatening visceral lesions. Germline gain-of-function mutations in PDGFRB have been identified as the most common molecular defect in familial IM. CASE PRESENTATION: We here describe an infant with PDGFRB-driven IM with multiple tumors at different sites, including intestinal polyposis with hematochezia, necessitating temporary chemotherapy. CONCLUSIONS: PDGFRB-driven IM is clinically challenging due to its fluctuating course and multiple organ involvement in the first years of life. Early molecular genetic analysis is necessary to consider tyrosine kinase inhibitor treatment in case of aggressive visceral lesions.
BACKGROUND:Infantile myofibromatosis (IM) is the most common cause of multiple fibrous tumors in infancy. Multicentric disease can be associated with life-threatening visceral lesions. Germline gain-of-function mutations in PDGFRB have been identified as the most common molecular defect in familial IM. CASE PRESENTATION: We here describe an infant with PDGFRB-driven IM with multiple tumors at different sites, including intestinal polyposis with hematochezia, necessitating temporary chemotherapy. CONCLUSIONS:PDGFRB-driven IM is clinically challenging due to its fluctuating course and multiple organ involvement in the first years of life. Early molecular genetic analysis is necessary to consider tyrosine kinase inhibitor treatment in case of aggressive visceral lesions.
Authors: Susan Y Wu; Timothy L McCavit; Kevin Cederberg; Rene L Galindo; Patrick J Leavey Journal: J Pediatr Hematol Oncol Date: 2015-07 Impact factor: 1.289
Authors: Yee Him Cheung; Tenzin Gayden; Philippe M Campeau; Charles A LeDuc; Donna Russo; Van-Hung Nguyen; Jiancheng Guo; Ming Qi; Yanfang Guan; Steffen Albrecht; Brenda Moroz; Karen W Eldin; James T Lu; Jeremy Schwartzentruber; David Malkin; Albert M Berghuis; Sherif Emil; Richard A Gibbs; David L Burk; Megan Vanstone; Brendan H Lee; David Orchard; Kym M Boycott; Wendy K Chung; Nada Jabado Journal: Am J Hum Genet Date: 2013-05-23 Impact factor: 11.025
Authors: John A Martignetti; Lifeng Tian; Dong Li; Maria Celeste M Ramirez; Olga Camacho-Vanegas; Sandra Catalina Camacho; Yiran Guo; Dina J Zand; Audrey M Bernstein; Sandra K Masur; Cecilia E Kim; Frederick G Otieno; Cuiping Hou; Nada Abdel-Magid; Ben Tweddale; Denise Metry; Jean-Christophe Fournet; Eniko Papp; Elizabeth W McPherson; Carrie Zabel; Guy Vaksmann; Cyril Morisot; Brendan Keating; Patrick M Sleiman; Jeffrey A Cleveland; David B Everman; Elaine Zackai; Hakon Hakonarson Journal: Am J Hum Genet Date: 2013-05-23 Impact factor: 11.025